Daxor Corporation announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor's BVA-100 (Blood Volume Analyzer, BVA) technology in hospitalized COVID-19 patients. NYU Langone Health, Wake Forest School of Medicine and OHSU have been enrolling subjects since the onset of the pandemic.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.2 USD | 0.00% | +2.22% | -4.17% |
07-11 | Daxor Corporation?s BVA-100? Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide | CI |
06-05 | Daxor Corporation Appoints John L. Jefferies as Chief Medical Officer | CI |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.17% | 44.5M | |
+5.19% | 12.95B | |
+18.32% | 9.95B | |
+2.05% | 5.71B | |
+28.34% | 5.12B | |
+5.68% | 5.19B | |
-8.49% | 5.04B | |
+25.46% | 4.77B | |
+4.11% | 3.99B | |
-2.81% | 3.82B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Announces Patient Enrollment Completion and Updates Data Analysis